Compare AAT & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | TNDM |
|---|---|---|
| Founded | 1967 | 2006 |
| Country | United States | United States |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | 2013 |
| Metric | AAT | TNDM |
|---|---|---|
| Price | $22.04 | $19.90 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $19.50 | ★ $28.00 |
| AVG Volume (30 Days) | 375.4K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $436,204,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $4.33 | $8.11 |
| Revenue Next Year | $0.22 | $11.85 |
| P/E Ratio | $278.13 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $17.72 | $11.46 |
| 52 Week High | $25.97 | $29.65 |
| Indicator | AAT | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 44.89 |
| Support Level | $22.24 | $19.70 |
| Resistance Level | $23.15 | $20.79 |
| Average True Range (ATR) | 0.32 | 1.14 |
| MACD | 0.01 | -0.44 |
| Stochastic Oscillator | 12.20 | 4.39 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.